pharma · Multiple Myeloma · Relapsed/Refractory Multiple Myeloma
Janssen-Cilag International N.V
Janssen-Cilag International N.V.
Janssen-Cilag Farmaceutica Ltda is a pharma organization headquartered in São Paulo, EU. Primary therapeutic focus areas include Multiple Myeloma, Relapsed/Refractory Multiple Myeloma, Inflammatory Conditions, Moderately
Company details
- Status
- Public
- HQ
- São Paulo, EU
- Employees
- 13
- Programs
- 161
- Drugs
- 159
- Patents
- 0
A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors
Phase 1 · other · Locally advanced, metastatic NSCLC, CRC, or HNSCC that has recurred or progressed after prior stand of care therapy
A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors for Locally advanced, metastatic NSCLC, CRC, or HNSCC that has recurred or progressed after prior stand of care therapy is a Phase 1 program (other) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Internal code 95437446LUC1001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Janssen-Cilag International N.V.
- Phase
- Phase 1
- Modality
- other
- Indication
- Locally advanced, metastatic NSCLC, CRC, or HNSCC that has recurred or progressed after prior stand of care therapy
- Status
- active
- Trials
- 1